SEINE BIO · SCIENCE LIBRARY
Eloralintide
Eloralintide is a selective long-acting amylin receptor agonist in metabolic clinical development.
Research compoundA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Eloralintide.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Overview
Eloralintide, also known by the development code LY3841136, is an investigational selective amylin-receptor agonist. Researchers are studying it for weight management. It is not simply another brand of an established GLP-1 prescription. Its appeal should be assessed through the actual human trials, formulation, and development status rather than through the word peptide alone.
Community Use
PeptideDosages has an Eloralintide vial protocol, reflecting growing community interest in an early clinical candidate. That page is a community source and does not create a clinical indication or dispensing authorization. A consumer chart must not replace the trial’s population, monitoring, or sponsor-manufactured formulation. Observed community protocol.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous injection | Trial arms: 1, 3, 6 or 9 mg weekly; additional arms escalated from 6 to 9 mg or from 3 to 9 mg. | Once weekly in the cited trial | 48-week treatment period Break: No informal off-cycle established by this source | Human study regimen Billings et al., Lancet 2025; 48-week eloralintide phase 2 trial |
| Subcutaneous | Calls 1 mg a common start or baseline and describes a 1–3 mg range; calculator chart separately displays 0.5, 1, 1.5 and 2 mg weekly. | Once weekly | No total course for the common-dose chart; an alternative trial section cites 48 weeks. Break: Not stated | Published informal biohacking claim Peptide Protocol Wiki |
| Subcutaneous | Community section records a common 1 mg weekly start, increases every few weeks, and reported targets of 3–9 mg weekly. | Once weekly | No community course length specified; 48 weeks is explicitly the separate phase 2 trial period. Break: Not stated | Published informal biohacking claim PeptideX |
Important context: These are experimental fixed-dose and escalation arms. The lowest arm is not an established clinical starting dose, and 9 mg is not an approved safe maximum.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
A published phase 1 study used once-weekly subcutaneous investigational treatment during a 12-week multiple-ascending-dose study. Its individual study arms are research exposures, not a validated outpatient start, escalation, or cycling plan. The absence of escalation within that specific experiment should not be generalized into a future prescribing instruction.
Research Findings
The 2026 report describes a randomized early-phase study of 100 participants with overweight or obesity. Safety and tolerability were major outcomes, alongside pharmacokinetics and exploratory weight measures. The short duration and selected population limit conclusions about long-term treatment. Human phase 1 trial.
U.S. Approval & Access
No FDA-approved Eloralintide product was established by this review. Early human results do not turn a research-vial listing into an approved weight-loss option. A future approval would define the actual product, population, warnings, and prescribing instructions; until then, study access is controlled by legitimate research teams.
What It Does in the Body
Amylin-related signaling is involved in appetite and food-intake regulation. Eloralintide was designed for selective activity at that receptor system. The mechanism helps frame a research question, but does not show how it will compare with other medicines in practice or how an individual with several medical conditions would respond. Reliable onset, peak clinical benefit, and duration for a proposed consumer Eloralintide program are not established by this early trial.
Benefits & Reported Experiences
The study reported dose-related exploratory weight reductions. That finding is evidence for further testing, not proof of a preferred dose or a guaranteed outcome. Weight changes in a short early-phase experiment should be considered alongside the number of participants, withdrawals, and the purpose of the trial.
Side Effects & Risks
Reported adverse events included decreased appetite, headache, fatigue, and gastrointestinal symptoms; most were mild in the cited report. The result does not establish that rare events are absent or that longer exposure is equally tolerable. A small trial can characterize a signal without defining the complete safety profile.
Delivery Options
The relevant evidence uses a specific subcutaneous investigational product. It does not validate a different supplier’s preparation or an alternative route. Route and formulation are essential details when discussing human exposure. This library does not describe injection steps, mixing, or unsupervised use of research powders.
Product Quality & Storage
The meaningful quality comparison is with the product and controls in the actual study, not with a generic peptide purity claim. A vial label may communicate concentration while leaving pharmacological identity and clinical suitability unresolved. Research-only products should not be treated as interchangeable with a sponsor’s trial supply. Study-product handling is controlled by the research program; a community vial page cannot establish verified storage instructions for patient use.
Combinations & Interactions
Community interest in pairing an amylin candidate with other weight-loss drugs does not establish a studied combination. Different amylin molecules and GLP-1 therapies have different development programs. A combination should be identified precisely rather than inferred from separate studies or from a familiar appetite-related mechanism.
Talking With Your Provider
If appetite, weight regain, or prior treatment intolerance brought you to this page, a consultation can address those concerns without promising Eloralintide. Ask about available evidence-based options and what would make a research study appropriate. Trial eligibility, approval status, and individual suitability remain separate decisions.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Metabolic health & weight-management scienceEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →